{
    "2021-06-11": [
        [
            {
                "time": "2023-10-17",
                "original_text": "AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment",
                "features": {
                    "keywords": [
                        "Venclexta",
                        "Progression-Free Survival",
                        "CLL Patients",
                        "Three Years Treatment"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market",
                "features": {
                    "keywords": [
                        "Cheap Stocks",
                        "Expensive Market"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "New Data Shows AbbVie's VENCLYXTO速/VENCLEXTA速 Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment",
                "features": {
                    "keywords": [
                        "VENCLYXTO速",
                        "VENCLEXTA速",
                        "Fixed Duration Combination",
                        "Progression-Free Survival",
                        "Chronic Lymphocytic Leukemia",
                        "Three Years off Treatment"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}